New Drug approved in UK:

Prucalopride

The motility agent, Prucalopride (similar to Cisapride/Propulsid) was approved for use in the UK. Trials have shown little to no indication of cardiac side effects in conjunction with Prucalopride, the main reason other drugs have been pulled from the market in the US and other countries.

G-PACT has contacted the drug company about the possibility and timeframe of pursuing approval in the US. Our FDA patient advocates will also be working closely with the FDA in order to aid in the process of getting this medication approved.

*G-PACT provides factual information on studies as they are given to us, but we do not endorse or promote any particular study, treatment, or company. Each study we post is for informational purposes to provide a guideline and should be discussed thoroughly with a qualified physician to ensure it is appropriate for you and your condition(s). No positive results or benefits are guaranteed.